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Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this 
study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-
line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or 
intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median 
progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7–3.5). Median 
overall survival was 12.0 months (95% CI: 10.7–15.8) in patients receiving capecitabine, while 9.0 
months (95% CI: 6.5–13.9) in patients receiving BSC. The result of univariate unweighted Cox regression 
model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357–0.829; p  =0.005) 
compared to patients receiving BSC alone. After weighting for potential confounders, death risk 
remained essentially unaltered (45%; 95%CI: 0.354–0.883; p = 0.013). Metronomic capecitabine seems 
a safe second-line treatment for HCC patients in terms of management of adverse events, showing a 
potential anti-tumour activity which needs further evaluation in phase III studies.
Hepatocellular carcinoma (HCC) represents the commonest primary liver cancer with increasing incidence. HCC 
is the 5th most widespread malignancy globally and the 3rd leading cause of cancer-related death1. Unfortunately 
most patients are diagnosed at an advanced stage when curative treatments are no longer an option.
The introduction of Sorafenib, currently representing the standard of care for advanced HCC2 and no proven 
second-line therapy is yet available for HCC patients and current guidelines recommend either best supportive 
care (BSC) or clinical trial enrolment3. According to recent studies, only 41–56% of patients failing first-line 
systemic therapy are potentially eligible for second-line clinical trials on the basis of clinical and biochemical 
eligibility criteria4–5. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which is metabolised to 5-FU in a 
three-step enzymatic reaction, the last of which being the conversion in the liver and in the tumour by thymidine 
phosphorylase6. The concept of metronomic chemotherapy has been introduced in oncology in recent years7. 
Metronomic use of anti-cancer drugs can be considered as a type of “dose-dense” chemotherapy, although differ-
ing from traditional dose-dense administration. It is neither “dose-intense”, since it does not deliver more total 
drug per unit time, nor is it a cyclic maximum tolerated dose regimen with a three-week break period between 
cycles6. Metronomic regimens are less toxic, reporting reduced bone marrow toxicity and gastrointestinal 
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disorders, including vomiting, nausea, mucositis and liver dysfunction. Metronomic chemotherapy was studied 
in different tumors8,9.
Preliminary studies suggested that capecitabine may be safe and effective in HCC patients10–16.
The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as 
second-line treatment in patients who had progressed or were intolerant to first-line sorafenib.
Patients and Methods
In this multicentric study we retrospectively analysed data of HCC patients unresponsive or intolerant to 
sorafenib.
Patients with advanced- or intermediate-stage HCC (either histologically proven or diagnosed according to 
the AASLD [American Association for the Study of Liver Diseases 2005] guidelines) unresponsive or intolerant 
to sorafenib, were eligible for our analysis. Sorafenib unresponsive is defined as a increase of at least 20% in the 
sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters 
of viable (enhancing) target lesions recorded since the treatment started or new appearance of one or more new 
lesions of any size.
Sorafenib intolerance is defined as CTCAE Grade ≥2 drug-related adverse event which persisted in spite of 
comprehensive supportive therapy according to institutional standards and persisted or recurred after sorafenib 
treatment interruption of at least 7 days and dose reduction by one dose level (to 400 mg once daily).
Patients treated with capecitabine received the therapy at the metronomic dosage of 500 mg every 12 h. The 
centers treated the patients with metronomic capecitabine whenever they were uneligible for protocol enrol-
ment or the center had no second-line clinical trials ongoing. Eligibility criteria included: Eastern Cooperative 
Oncology Group (ECOG) performance status score of ≤2; Child–Pugh liver function class A or B7; adequate 
hematologic function (platelet count, ≥60 × 109/L; hemoglobin ≥8.5 g/dL; and prothrombin time international 
normalized ratio ≤2.3 or prothrombin time ≤6 seconds above control]; alanine aminotransferase and aspartate 
aminotransferase ≤5 times the upper limit of the normal range); and adequate renal function (serum creati-
nine ≤1.5 times the upper limit of the normal range). Dose reductions applied when clinically indicated. Grade 
3/4 adverse events (AEs) led to dose modification (500 mg daily) or temporary interruption, until symptoms 
resolved to grade ≤2. Follow-up consisted of a CT/MRI scan every 8 weeks or as clinically indicated. Tumor 
response was evaluated by modified Response Evaluation Criteria in Solid Tumors (mRECIST)17. Treatment with 
capecitabine was continued until disease progression, unacceptable toxicity or death.
Patients treated with BSC alone included patients eligible for second-line treatment (either metronomic 
capecitabine or clinical trial) but not complying with it. Eligibility criteria were the same as for patients treated 
with capecitabine.
The IRST-IRCCS-AVR Ethical Committee approved the study (approval number 1440). All patients included 
in the analysis were treated in accordance with the approved guidelines. Informed consent was obtained from all 
patients.
Statistical analysis
Frequency tables were performed for categorical variables. Continuous variables were presented using median 
and range. Overall survival (OS) was defined as the time from start date of Sorafenib to date of death. AE-free 
patients were censored on date of last follow-up. Progression-free survival (PFS) was defined as the time from 
start date of capecitabine to date of progression or death or last follow-up whichever occurred first. OS and 
PFS were reported as median values expressed in months, with 95% confidence interval (CI). Survival curves 
were estimated using the product-limit method of Kaplan-Meier. The role of stratification factor was analyzed 
with log-rank tests. Correction for multiple testing was done as appropriate, using the Benjamini and Hochberg 
method.
Propensity score (PS) is the conditional probability of being treated given a set of observed potential con-
founders. In this way all the information from a group of potential confounders is summarized into a single 
balancing score variable, the so-called PS. PS assures that the distribution of measured baseline covariates is 
maintained unchanged in treated and untreated subjects. Standardized difference was used as balance measure to 
compare the difference in means in units of the pooled standard deviation.
A weighted Cox Proportional Hazard model was performed including treatment with capecitabine as covar-
iate where all confounding factors had been controlled by weighting. PS weights were computed as 1/PS for 
patients treated with capecitabine and 1/(1-PS) for patients treated with BSC. Also an unweighted Cox regression 
model was performed.
The association between hand-foot skin reaction (HFS) and objective response (OR, defined as partial 
response and stable disease vs. progressive disease) was examined using the Chi-Square test.
P < 0.05 was considered statistically significant. Statistical analyses were carried out with STATA/MP 14.0 for 
Windows (Stata Corp LP, USA).
Results
One hundred and thirteen consecutive patients with HCC were available for the analysis. 58 patients were 
treated with capecitabine from May 2011 to November 2015, and 55 patients were treated with BSC alone from 
December 2007 to September 2015. IRST-IRCCS recruit 38 patients treated with capecitabine and 45 patients 
treated with BSC. Department of Medical Oncology of Cagliari recruit 6 patients treated with capecitabine and 
10 patients treated with only best supportive care. Department of Medical Oncology of Rimini recruit 5 patients 
treated with capecitabine. Department of Medical Oncology of the National Cancer Institute “Giovanni Paolo II” 
recruit 6 patients treated with capecitabine, Department of Onco-Ematology of Taranto recruit 3 patients treated 
with capecitabine.
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Patient characteristics for the two groups are shown in Table 1. Among the capecitabine patients 44 (75.9%) were 
males and 14 (24.1%) females, with a median age of 67.5 years (range 37–82), while in the BSC group 42 patients 
(76.4%) were males and 13 (23.6%) females, with a median age of 73 years (range 28–87). Table 1 shows that patients 
with BSC alone and patients with capecitabine differed in age and AFP value. After application of PS, the stand-
ardized difference between patients on a second-line treatment and patients undergoing no further treatment was 
generally minor, which suggested that baseline characteristics between the two groups were equal (Table 2).
Median follow-up was 9 months (range 1–36 months). In patients treated with capecitabine median PFS was 
3.1 months (95%CI: 2.7–3.5) (Fig. 1). Median OS was 12.0 (95% CI: 10.7–15.8) for patients receiving capecit-
abine, and 9.0 (95% CI: 6.5–13.9) for patients treated with BSC (Fig. 2). The result from univariate unweighted 
Cox regression model showed 46% reduction of death risk for patients on capecitabine (95%CI: 0.357–0.829; 
p = 0.005), compared with patients on BSC alone. After weighting for potential confounders, death risk remained 
essentially unaltered (45%; 95%CI: 0.354–0.883; p = 0.013).
The best tumour response in patients treated with capecitabine was partial response in 3 patients (5.4%), 
stable disease in 21 patients (37.5%) and progression disease in 32 patients (57,1%), according to mRECIST cri-
teria. No complete response was observed. Twenty-three (39.7%) patients had at least one AE. The most frequent 
drug-related AEs were dermatologic toxicity (20.7%) and thrombocytopenia (6.9%) (Table 3).
Patients treated with capecitabine reported a significant association (p = 0.011) between the presence of HFS 
and disease control rate (Table 4).
OS with respect to patient baseline characteristics of both cohorts are also shown in Table 5. Among patients 
on capecitabine, better OS was reported by patients without viral infection (22.8 months [95%CI: 13.9–28.5]) 
than those with viral infection (10.9 months [95%CI 9.6–13.0]) (p = 0.0006). Among BSC patients, better OS was 
reported by patients with ECOG 0, meld score ≤10, LDH ≤ 220 and BCLC B. Corrections for multiple testing 
were made for OS in the two subgroups with unchanged results.
Variables Capecitabine N (%) BSC N (%)
Total 58 55
Sex
 Male 44 (75.9) 42 (76.4)
 Female 14 (24.1) 13 (23.6)
Age, Median (range) 67.5 (37–82) 73 (28–87)
Aetiology
 Non-viral 16 (27.6) 19 (34.6)
 Viral 42 (72, 4) 36 (65.4)
 Viral - HBV 11 (26.2) —
 Viral - HCV 31 (73.8) —
Child-pug score
 a 52 (89.7) 52 (94.5)
 b 6 (10.3) 3 (5.5)
BCLC stage
 b 7 (12.1) 10 (18.2)
 c 51 (87.9) 45 (81.8)
Performance status (ECOG)
 0 40 (69.0) 34 (61.9)
 1 16 (27.6) 17 (30.9)
 2 2 (3.4) 2 (3.6)
Portal hypertension
 No 44 (75.9) 35 (63.6)
 Yes 14 (24.1) 20 (36.4)
Meld index, Median (range) 9 (6–15) 8 (6–15)
 missing 29 0
AFP pre-treatment 166 (2–32, 784) 767 (1.1–43, 194)
 missing 8 6
LDH pre-treatment 220 (98–1, 035) 252.5 (132–588)
 missing 26 15
AFP pre-treatment, Median (range) 687 (1–46, 401) 216 (1.4–50, 000)
 missing 12 10
LDH pre-treatment, Median (range) 230 (25–918) 227 (194–419)
 missing 48 36
Table 1.  Patient characteristics.
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Discussion
In this study we evaluated the safety and efficacy of metronomic capecitabine as second-line treatment in a cohort 
of HCC patients not responsive to first-line sorafenib, using a dose schedule of 500 mg twice daily. Efficacy data 
analysis showed that 42.9% of the capecitabine-treated patients achieved disease control, with a median PFS 
of 3.1 months and a median OS of 12 months. The data obtained from this study were similar to those of other 
studies14,15: Brandi et al.16 achieved a median PFS of 3.27 months and a median OS of 9.77 months, while Granito 
et al. achieved a median time-to-progression of 4 months and median OS of 8 months. Compared with other 
Mean in capecitabine Mean in BSC Standardized differences
Sex 0.24 0.25 − 0.023
Age 63.95 65.36 − 0.125
Aetiology 0.72 0.72 0.011
Child-pug score 0.10 0.06 0.157
BCLC stage 1.88 1.86 0.058
PS (ECOG) 0.31 0.32 − 0.015
Portal hypertension 0.24 0.26 − 0.030
Sorafenib duration 0.64 0.49 0.313
Best response to Sorafenib 0.47 0.33 0.274
Table 2.  Checking balance of confounders between capecitabine and BSC group after weighting.
Figure 1. Median PFS of patients treated with capecitabine. 
Figure 2. Median OS of patients treated with capecitabine and BSC only. 
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studies on second-line treatments, capecitabine showed median PFS longer than tivantinib (2.7 months in the 
high c-Met expression subgroup), yet shorter than regorafenib (4.3 months)18.
Unlike to other studies on capecitabine, we additionally analysed patients treated with BSC alone. The data 
showed a reduction in death risk for patients on capecitabine, suggesting the efficacy of the metronomic capecit-
abine treatment, especially in patients without viral infection and with HCV viral infection. This data supports 
the possible biological difference between patients with and without viral infection19. This finding is consistent 
with previous study with chemotherapy indicating that HCC correlate with infection hepatitis B have a greater 
aggressiveness than non-virus-related tumors20. HBV related tumors have different genetic mutations with 
greater chromosome instability respect other etiologies and have higher prevalence of loss of heterozygosity21. 
These characteristics are correlated with tumor aggressiveness and lower response to chemotherapy.
It is noteworthy that survival-predictive baseline characteristics of patients treated with BSC matched those 
already known from the literature (Child-Pugh score, ECOG, meld score, LDH, BCLC stage)22, whereas patients 
treated with metronomic capecitabine presented no clinical characteristics predictive of survival other than posi-
tivity or negativity to viral infection. Another interesting fact is that metronomic capecitabine might have greater 
effectiveness in patients with poor prognosis at baseline than in patients with better prognosis: OS was 13.9 
months for BSC patients with ECOG 0 vs. 12.0 months for metronomic capecitabine patients; in patients with 
poor performance status (ECOG > 1) OS was 6.7 months for BSC treatment vs.13.0 months capecitabine treat-
ment (similar to patients with ECOG 0). Our data suggested a possible activity of capecitabine in patients with 
poor prognosis at baseline.
Metronomic chemotherapy can also be regarded as a form of long-term ‘maintenance’ chemotherapy that can 
be used alone, or combined with long-term biologic targeted therapies, especially anti-angiogenic drugs such as 
anti-VEGFR-2 antibodies or small molecule multitargeted VEGFR-2 antagonist receptor tyrosine kinase inhibi-
tors. A case report showed that high expression of VEGFR-2 was correlated with complete response in breast can-
cer patients treated with metronomic capecitabine9. The durable complete response to metronomic chemotherapy 
highlighted the importance of assessing potential predictors of benefit of this treatment, calling for further 
research on VEGFR2. More recently, other potential mechanisms of action have been suggested for metronomic 
chemotherapy involving anti-cancer immune response and other “actors” in the tumor microenvironment.
HFS is a common toxicity in patients treated with capecitabine23. In breast and colorectal cancer HFS was 
reported to be an independent predictor of treatment response to capecitabine24,25. Our data suggested that HFS 
may serve as an independent clinical predictor of treatment outcome.
Regorafenib in second line after sorafenib has been shown to increase survival respect to placebo26. Many 
promising drugs in phase II studies failed in subsequent phases trials, due to the faulty study design, especially for 
the stratification at the time of randomization, and other heterogeneous reasons, including lacking established 
prognostic factors after failure of sorafenib, no significant anti-tumour activity, and liver toxicity27,28.
The study has some limitations, due in particular to its retrospective nature (cases were, however, consecu-
tively selected, thus reducing potential bias). Lack of randomization, as a technique used to balance the effect 
of uncontrollable factors that can impact the results of an experiment, was limited applying propensity score to 
baseline variables.
The results from unweighted and weighted Cox regression model showed that the reduction of death risk 
for patients in capecitabine group, compared with patients on BSC alone, remained essentially unaltered after 
weighting for potential confounders showed in Table 2, so we can conclude that baseline and first line treatment 
characteristics, aren’t factor so strong to change risk of death of analyzed patients.
Total
Any grade N (%) Grade 1/2 N (%) Grade 3/4 N (%)
Overall 23 (39.7) 18 (31.0) 5 (8.6)
 Hypertension 2 (3.4) 2 (3.4) 0 (0.0)
 Hand-foot skin reaction 12 (20.7) 10 (17.2) 2 (3.4)
 Thrombocytopenia 4 (6.9) 4 (6.9) 0 (0.0)
 Edema lower limbs 2 (3.4) 2 (3.4) 0 (0.0)
 Asthenia 1 (1.7) 0 (0.0) 1 (1.7)
 Anemia 1 (1.7) 0 (0.0) 1 (1.7)
 Heart failure 0 (0.0) 0 (0.0) 1 (1.7)
Table 3.  Toxicity.
N (%)
Cutaneous toxicity (any grade)
p-value*No Yes
PD 32 (57.1) 29 (65.9) 3 (25.0)
0.011
SD + PR 24 (42.9) 15 (34.1) 7 (75.0)
Not Evaluable 2
Table 4.  Best response to capecitabine and cutaneous toxicity.
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In conclusion, metronomic capecitabine seems safe in the second-line treatment of HCC patients in terms 
of management of AE, showing potential anti-tumour activity, which requires further evaluation in phase III 
studies.
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